Cutaneous Reactions in Pediatric Patients Treated with MEK Inhibitors- A Retrospective Single Center Study.

Introduction MEK inhibitors are in use for several indications for adults and children. Cutaneous toxicities are among the most common adverse effects. We aimed to describe the spectrum of cutaneous adverse events, its frequency and severity in a cohort of pediatric patients. Methods We reviewed all records of patients in our tertiary treatment center treated with MEK inhibitors between January 2016 and January 2023 for all indications. Results Among 33 patients, 76% reported cutaneous adverse effects. The highest prevalence was in the group of patients treated with trametinib (90%), followed by the group treated with selumetinib (50%) and the group treated with combination of trametinib and BRAF inhibitor (dabrafenib, 34%). Xerosis, dermatitis, paronychia and hair heterochromia were most frequently reported. Severity was graded 1 or 2 for most adverse events, and 237 visits to the dermatology clinic related to these adverse events were recorded. Conclusions Cutaneous adverse events are common in the pediatric population as in adults, but the clinical spectrum is different. Although considered as mild, multiple dermatological consultations reflect the distress caused by these events. Dermatologists have a central role in the multidisciplinary care of pediatric patients receiving these agents.

Pigmented demodicidosis - an under-recognized cause of facial hyperpigmentation.

BACKGROUND: There is a paucity of data regarding demodicidosis-associated facial hyperpigmentation. OBJECTIVE: To delineate the clinical, dermoscopic, and histopathologic features of demodicidosis-associated facial hyperpigmentation. METHODS: Clinical and diagnostic data were collected from the medical files of patients who were referred to our outpatient dermatology clinic in 2006-2019 for evaluation of facial hyperpigmentation and were diagnosed with demodicidosis. RESULTS: The cohort included 19 patients (13 male) aged 42-76 years, all with Fitzpatrick skin type 3-4. All presented with mostly asymptomatic dusky, brown-gray, facial pigmentation, localized or diffuse with background erythema in 36.8% of cases, and skin roughness in 26.3%. Dermoscopy yielded characteristic findings of white gelatinous or opaque protrusions from hair follicles or infiltration of follicular openings with an amorphic material. A specific finding was perifollicular and reticulated pigmentation of the affected areas. Findings were confirmed on microscopic (n = 7) and histopathologic (n = 5) studies. Anti-demodectic treatment led to complete (73.6%) or partial (23.4%) resolution of pigmentation within 2 years. CONCLUSION: We describe unique clinicopathological and dermoscopic findings associated with an under-recognized type of facial hyperpigmentation caused by demodex for which we propose the term "pigmented demodicidosis." Demodicidosis should be added to the list of causes of facial hyperpigmentation.

Quantification of metamorphopsia using the MacuFlow test before and after vitreoretinal surgery.

BACKGROUND AND OBJECTIVE: This pilot study evaluated the clinical utility of the MacuFlow software in measuring metamorphopsia prior to and following surgery in patients with vitreoretinal diseases. PATIENTS AND METHODS: Four patients with vitreoretinal disorders causing metamorphopsia were included in this pilot study. Visual acuity (VA), optical coherence tomography and MacuFlow scores were recorded prior to and following surgical intervention. RESULTS: The mean preoperative VA was 0.59 ± 0.09 logMAR, central macular thickness 491.2 ± 41.3 µm and calculated macular volume 8.99 ±1.47 mm(3). These parameters improved postoperatively to a mean VA of 0.30 ± 0.22 logMAR, central macular thickness of 372.8 ± 85.4 µm and macular volume of 7.94 ± 1.34 mm(3) but did not reach statistical significance. The mean preoperative MacuFlow score was 14.02 ± 8.21, which significantly improved postoperatively to 5.4 ± 3.13 (p = 0.045). CONCLUSIONS: This is the first study to demonstrate the clinical utility of MacuFlow for the quantification of metamorphopsia and its improvement or resolution following surgery. This simple method may be a valuable addition for the clinical assessment and monitoring of patients with retinal diseases causing metamorphopsia.

Quantifying metamorphopsia in patients with diabetic macular oedema and other macular abnormalities.

PURPOSE: To quantify subjective visual metamorphopsia in newly diagnosed patients suffering from diabetic macular oedema (DME) and other macular abnormalities and to evaluate anti-VEGF treatment effect. METHODS: Patients with DME, subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or retinal venous occlusion (RVO) were recruited. Metamorphopsia score (Mscore) was calculated using M-Charts at baseline and at the end of a series of anti-VEGF injections. RESULTS: Fifteen eyes of 10 patients with DME, 14 eyes of 13 patients with AMD-CNV and five patients with RVO were included in this study. At baseline, positive Mscore was observed in 46.6% of eyes with DME, 50% of eyes with AMD-CNV and four of five eyes with RVO. Treatment led to a complete metamorphopsia reduction (Mscore = 0) in 71.4% of DME patients, 35.7% of AMD and 0% of RVO patients. CONCLUSION: We suggest that the M-charts may serve as an additional test for diagnosis and follow-up, complementary to morphological evaluation by imaging, in diabetic patients facing their first anti-VEGF treatment.